Popular Articles
Stretch Mark Cream

Joseph P. Vande Griend Receives 2009 APhA Clinical Research Paper Award
The American Pharmacists Association (APhA) is pleased to announce that Joseph P. Vande Griend, PharmD, BCPS, of Denver, Colorado, is the recipient of the 2009 APhA Clinical Research Paper Award. The award was presented during the APhA Annual Meeting and Exposition in San Antonio, Texas, April 3-6, 2009.
generic viagra online
Merck Issues Statement On WHO Study Showing First Evidence That Elimination Of River Blindness Is Feasible In Africa
Merck & Co., Inc. issued the following statement in response to study results published today by the World Health Organization offering the first evidence that elimination of the tropical disease river blindness (onchocerciasis) in Africa is feasible with treatment with ivermectin (registered trademark Mectizan®). As the discoverer and manufacturer of Mectizan, Merck decided in 1987 to donate the drug to all who need it for as long as necessary until river blindness is eliminated as a public health problem. The Merck Mectizan Donation Program is one of the longest-running disease-specific drug donation and public/private partnership programs in history. Drugshop to buy zoloft online and other pills.
News of the day
Collaborative Drug Discovery Partnership To Advance Cancer Drug Development
SRI International, an independent nonprofit research and development organization, has announced that SRI"s Center for Cancer Research was selected by the National Cancer Institute (NCI) for a leading role in the newly-formed "Chemical Biology Consortium" (CBC), a collaborative drug discovery partnership focused on advancing new cancer therapeutics active against novel molecular and genetic cancer targets. Based on its track record of cancer drug discovery and development, SRI was chosen to lead three of the CBC"s research and development centers: Comprehensive Chemical Biology Screening, Chemical Diversity, and Specialized Applications.
Medical Devices

Colorectal Cancer - MDC Researchers Identify Genetic Markers For Metastasis Formation

Previously, only a few genes had been associated with the formation of metastases in colorectal cancer. Now, researchers of the Max DelbrÃøck Center for Molecular Medicine (MDC) Berlin-Buch and Charité - University Medicine Berlin, Germany, have identified 115 genes that are disregulated both in the primary tumor and in its metastases. In the future, their findings may help identify patients with aggressive tumors at an earlier stage (Gastroenterology 2009, doi:10.1053/j.gastro.2009.03.041).* The National Cancer Institute estimates that, alone in the United States, 106,100 cases of colon cancer will occur and 49,920 patients will die both from colon and rectal cancer in 2009. Beginning in glands in the bowel lining, colorectal cancer often remains undiscovered initially. "However, the main problem is not the primary tumor," explained the surgeon and clinical researcher Dr. Johannes Fritzmann, "but the dangerous metastases." Metastases arise when single cells break off from the primary tumor and spread to other body regions via the blood vessels or the lymphatic system. In colorectal cancer, these cells usually settle in the liver, lungs, or lymph nodes. Since the affected patient seldom feels pain or shows other symptoms, the tumor is frequently not discovered until it has already formed metastases. To investigate which genetic mutations favor the formation of metastases, the researchers analyzed 150 tissue samples of colorectal cancer patients with and without metastases. The researchers identified 115 genes that are falsely regulated in both the primary tumors and their metastases. In this way, the researchers succeeded in identifying a genetic signature which distinguishes tumors with metastatic potential from those that do not metastasize. Of the 115 genes the researchers identified, they focused on one gene in particular: BAMBI. They discovered that this gene is more active in metastatic tumors and metastases than in non-metastatic tumors. "Our investigations show that the particular gene BAMBI is associated with two import signaling pathways and thus promotes metastasis formation," Dr. Fritzmann said. "These signaling pathways (Wnt and TGF-beta) are, among other things, important in the developing embryo." In the future the researchers want to investigate the role of the other 114 genes more closely, in order to better understand the individual steps of metastasis formation. Aim - To predict at an early stage whether the tumor will spread Dr. Fritzmann hopes the research findings will help determine early on whether a tumor has metastatic potential. The doctors could then adapt the therapy accordingly. *A Colorectal Cancer Expression Profile that Includes Transforming Growth Factor Ãÿ Inhibitor BAMBI Predicts Metastatic Potential Johannes Fritzmann1,2,6, Markus Morkel1,4,6, Daniel Besser1,6, Jan Budczies3, Frauke Kosel1, Felix H. Brembeck1,5, Ulrike Stein1,2, Iduna Fichtner1, Peter M. Schlag1,2 and Walter Birchmeier1 1 Max Delbrueck Center for Molecular Medicine, 13125 Berlin, Germany 2 Dept. for Surgery and Surgical Oncology, Charité - University Medical School, 13125 Berlin, Germany 3 Institute for Pathology, Charité - University Medical School, 10117 Berlin, Germany 4 present address: Max Planck Institute for Molecular Genetics, 14195 Berlin, Germany 5 present address: Dept. of Hematology and Oncology, University Göttingen, 37075 Göttingen, Germany 6 contributed equally. Barbara Bachtler Press and Public Affairs Max DelbrÃøck Center for Molecular Medicine (MDC) Berlin-Buch Robert-Rössle-StraÃÿe 10 13125 Berlin, Germany


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):